Literature DB >> 15848676

Infectious complications limit the outcome of liver transplantation in medical urgency code 2 patients.

W Mark1, I Graziadei, D Bargehr, W Vogel, C Boesmueller, W Tabarelli, A Pomarolli, R Ladumer, W Steurer, A Koenigsrainer, R Margreiter, H Bonatti.   

Abstract

The Organ shortage has caused an accumulation of acutely decompensated patients listed as medical urgency code 2 (MUC 2) (United network for Organ Sharing 2) while awaiting liver transplantation. Between June 1997 and June 2003, 22 of 360 liver transplantation patients (6%) were listed as MUC 2. Prophylactic immunosuppression consisted of calcineurin inhibitor-based drug therapy, using antithymocyte globulin or interleukin-2 receptor antagonist induction in 64%. The overall perioperative infection rate was 50%, and the rejection rate was 23%. We observed 7 episodes of oral or genital herpes simplex virus lesions; 2 patients (both with cytomegalovirus-mismatched transplants) developed cytomegalovirus disease, and another 5 patients received ganciclovir for preemptive therapy or prophylaxis. Two patients developed pneumonia: 5, sepsis that originated in 4 cases from a contaminated central venous line; and 1 methicillin-resistant endocarditis, which resulted in Staphylococcus aureus lethal outcome. After a median follow up of 3 years, 1 patient underwent a repeat transplantation procedure and 6 patients had died, 4 of them from infectious complications. Liver transplantation of MUC 2-listed patients may result in acceptable results similar to those of MUC 3 and MUC 4 categories.

Entities:  

Mesh:

Year:  2005        PMID: 15848676     DOI: 10.1016/j.transproceed.2004.12.253

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

Review 1.  A meta-analysis of complications following deceased donor liver transplant.

Authors:  Lisa M McElroy; Amna Daud; Ashley E Davis; Brittany Lapin; Talia Baker; Michael M Abecassis; Josh Levitsky; Jane L Holl; Daniela P Ladner
Journal:  Am J Surg       Date:  2014-07-18       Impact factor: 2.565

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.